Member Info for TR64

its been tested and failed against the brazilian virus, and Sanofi/GSK have stepped in to help produce the Biontech Pfizer vaccine, which todate is the best of what is available.

Unfortunately
AZN and Nahdim Zahawi the rook are failing and hoodwinking UK citizens with a vaccine that at best achieves 62% efficacy, those are the facts.

The EU invested £3 billion in vaccines, it invested 3 times more in AZN than the UK government, so when they refuse to issue l licenses that allow the vaccines to leave the EU they are well within contractual agreements on all Pharma companys

Both are stepping in and assisting Biontech/pfizer to increase supply, they will boost the production by 350 million doses, and supply the EU First

Its time the shady AstraZeneca gang if rooks were held to account, they fail to keep contracts and will face Tariffs in the EU
Personally, I am not bothered about the Oxford AZN vaccine, its a failure to do trials properly and to provide details of data..
Only 62% efficacy and it does not work on new strains, where as Biontech and Moderna show up well on new strains.

AZN should know now.. Vaccines leaving the EU “need a license, the EU can and should stop the license , thus the UK can take on the manufacture of the vaccine, and not Belgium Factorys

GSK ranks 1st in the 2021 Access to Medicine Index with leading R&D pipeline for priority diseases

GSK leave AZN, Pfizer, Merck, trailing in there wake

Ranking reflects GSK leadership through access to its medicines and vaccines for people around the world
Company extends albendazole donations with WHO for control of soil-transmitted helminthiasis in school-aged children to 2025, adding to existing commitment to elimination of lymphatic filariasis
The Access to Medicine Index (ATMI) published its 2021 report today, with GSK again ranking 1st among 20 of the world’s largest pharmaceutical companies. The independently developed, investor-backed Index is based on progress companies are making in improving access to medicine in 106 low- and middle-income countries and in relation to 82 diseases, conditions and pathogens.

GSK’s overall ATMI score improved from the 2018 Report, reflecting the company’s clear access-to-medicine strategy embedded within overall company strategy, and the application of its scientific innovation to address global health priorities - with the largest R&D pipeline compared to peers targeting priority diseases impacting people in low- and middle- income countries.

The report also further highlights the significance of cross-industry and cross-sector collaboration in improving the health of people in developing countries. A number of collaborations aligned to GSKs Global Health priority areas were recognised, including the development of paediatric formulations of dolutegravir for HIV; licencing its tuberculosis vaccine candidate to the Gates MRI for development and use in low-income countries; and collaboration with WHO, PATH and Ministries of Health to implement the RTS,S vaccine for malaria in Ghana, Kenya, and Malawi. The Index also recognises the breadth of ViiV Healthcare’s voluntary licensing for dolutegravir and the impact of GSK’s work with GAVI.

Emma Walmsley, Chief Executive Officer, GSK, said: “We are delighted to top the Access to Medicine Index once again and that our innovation in priority diseases affecting global health has been recognised. Our position reflects the outstanding contributions of our people, who work in labs and manufacturing sites across GSK, to bring medicines and vaccines to people around the world. This would also not be achieved without the help of our many partners and I would like to thank and recognise all those we work with in global health. Looking ahead, we remain strongly committed to improving research, access and development of new medicines and vaccines for global health diseases, in particular HIV, TB and malaria, future pandemics and antimicrobial resistance.”
https://www.gsk.com/en-gb/media/press-releases/gsk-ranks-1st-in-the-2021-access-to-medicine-index-with-leading-rd-pipeline-for-priority-diseases/

Hepatitis Antigen drives VIR to $69.00
https://www.nasdaq.com/articles/stock-alert%3A-vir-biotechnology-up-40-on-positive-data-for-vir-3434-2021-01-26

RC

GSK vaccine with Medicago will surprise a few, but GSK are extremely confident on CVAC, they took another 1 million shares today in CVAC

VIR Hit $ 69 72
GSK Own 6,75% of the shares in Issue.
All Brokers marked it down at $23.00

They talk B0ll0cks like Credit suiess

TA.

GSK are focused on CVAC vaccine, as its efficacy will be high 90's that can not be achieved by GSK or AZN
The variants already show AZN is not protecting, hence why the UK as halted travel from Brazil /Portugal

Moderna is currently be tested on the Brazilian Strain.

DMP

IMCR and GSK

Part of new release , OPEN link to read all detail on VIR chronic hepatitis B virus on https://investors.vir.bio/news-releases/news-release-details/initial-data-ongoing-phase-1-trial-vir-3434-chronic-hepatitis-b
Novel HBV-neutralizing monoclonal antibody with therapeutic vaccine potential demonstrated a mean HBsAg reduction from baseline of 1.3 log10 IU/mL by day eight –

SAN FRANCISCO, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced initial topline data from its ongoing trial of VIR-3434 in patients with chronic hepatitis B virus (HBV) infection. Data from the first blinded cohort of eight patients, two of whom received placebo and six of whom received a single dose of 6 mg of VIR-3434, showed that six of eight patients achieved a mean reduction of 1.3 log10 IU/mL in serum hepatitis B virus surface antigen (HBsAg) by day eight, the day when nadir was achieved in most patients.

VIR-3434 is an HBV-neutralizing monoclonal antibody designed to block entry of all 10 genotypes of HBV into hepatocytes and reduce the level of virions and subviral particles in the blood. It has also been Fc engineered to include the XX2 “vaccinal mutation,” allowing it to potentially function as a T cell vaccine, in this case, against HBV. The XX2 vaccinal mutation, which has the potential to transform standard antibodies into T cell vaccines, has also been incorporated into one of Vir’s investigational COVID-19 monoclonal antibodies, VIR-7832, which is currently planned to enter a Phase 1b/2a trial this quarter. Vir has licensed exclusive rights to the XX2 mutation for use in infectious diseases.

“The need for a functional cure for the nearly 300 million people living with chronic HBV is paramount. Lowering HBsAg may help unlock a patient’s immune system, allowing it to provide the immune control necessary to achieve a functional cure,” said Kosh Agarwal, M.D., lead study investigator and consultant hepatologist and transplant physician at the Institute of Liver Studies, King’s College Hospital NHS Foundation Trust in London. “These early, first-in-patient results are exciting because they demonstrate that even at a very low dose, VIR-3434 is able to markedly lower HBsAg.”

“Extrapolating from our preclinical data, we expected it might require much higher doses of VIR-3434 to achieve this level of HBsAg knockdown. To have achieved it with a dose of 6 mg is unexpected,” said Phillip Pang, M.D., Ph.D., Chief Medical Officer of Vir. “Coupled with initial data that shows VIR-3434 was well tolerated at up to 3,000 mg in healthy volunteers, I am hopeful that we are seeing just the beginning of VIR-3434’s capabilities.”

dfslicker, then you can go an have a holiday in cornwall, they are charging £3000 per week for a caravan, but in the canaries you can get 5* hotel with Breakfast for £370 pp.

You take your Pick, wet and rainy Cornwall in a baked bean can or luxury and sunshine

Thats the actual efficacy rate on the vaccine Trail
62% Efficacy
Time will tell but another factor was the vaccine was not tested on anyone over 55 when it showed a fluke result of 78% efficacy based on 239 people.

All other trials have had over 40,000 people in them and were completed .
AZN trial as still not completed in the USA and was halted in Brazil Because of a Death during the trail, which no details were released, but presumed to be a placebo. The Trial in the USA was restarted on October 23.

The FDA are so strict, it makes the MHRA look like park wardens, but that comes down to Pharma company being able to be prosecuted and fined, which the UK does not apply the same strignet rules to protect people and pay compensation

RC.

AZN did not complete the trails in full, but its the UK choice, but anyone taking a vaccine that as a efficacy rate of 62% must realize that every 100 people vaccinated, 38 are still likely to get the Virus.

AZN and Pfizer are playing capitalization and running up costs, as both now are not able to complete orderrs and the Serum institute in India, where AZN vaccine is also made, has had a fire, you cant make this stuff up.

You can have good scientists and do things well, but AZN are profiteering, and I hope Biden makes AZN/Oxford repay the $1.2 billion

When you ask Arlene Weintraub about CVAC and VIR she says in reply she as not seen anything on them, when you ask her to explain how CVAC benefits GSK, her reply is what dose this CVAC have to do with GSK

Story here is simple, supped award wining journo in pharma market as lack of knowledge and fails to even condut the most basic of research

This is same old BS, itrs starts when CS write crap, and then GSK Merk cancel one trail on the basis its not shown the real results needed.

Merck know what they are doing and as someone who follows regulatory news . I note how these halb backed commentators don't focus on everything.

The HIV treatment is a game changer for 100 million people, the cancer treatment had a limited market, but was part of two major Pharmas working together.

Lets see how the press covered dostarlimab, yet this treatment covers more people, yet again the press and pharma mags dont get there heads round key issues like Zejula, which as now got Uk approavl after getting FDA and EU approval two years earlier

Jollifant.

Its not the case of missleading people the post was made clear of LN , and if you even understood Autoimmune, you would not the crossovers and overlaps . SLE is part of crossover and overlaps to 5 other autoimmune diseases.

I am not here for your pleasure to attempt to ridicule, I made the point that you need a good partner if you contract out in agreements.

IMM have let shareholders down and not been forthcoming, especially the partner they have . Who todate refuse to even reply on basics, its a real shame Shareholders have been treated shockingly by the board who partnered ther USA multiple company umbrella .

If you want to engage in crossovers and overlaps, then say, and I will share that side.
LN actually as a very direct impact on the heart disease resulting in heart failure.

Nolupus, Shame you do not understand the disease process .
hey but I am still hopeful .IMM get rid of its US partner and find s a real partner when conducting trials.

FDA APPROVES AURINIA PHARMACEUTICALS' LUPKYNIS(TM) (VOCLOSPORIN) FOR ADULT PATIENTS WITH ACTIVE LUPUS NEPHRITIS
January 22 - 2021 - 8.24 pm EST
- LUPKYNIS is the first FDA-approved oral therapy for lupus nephritis (LN), a condition that causes irreversible kidney damage and increases the risk of kidney failure, cardiac events, and death -

- LUPKYNIS demonstrated significantly improved renal response rates compared to typical standard-of-care (SoC) in clinical trials

- LUPKYNIS is now commercially available in the U.S. -

- Multimedia components are available with this press release ( link here ) -

- Conference call to be hosted Monday, January 25, 2021, 8:30 a.m. ET -

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved LUPKYNIS TM (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active lupus nephritis (LN). LUPKYNIS is the first FDA-approved oral therapy for LN. LN causes irreversible kidney damage and significantly increases the risk of kidney failure, cardiac events, and death. It is one of the most serious and common complications of the autoimmune disease systemic lupus erythematosus (SLE). LUPKYNIS is now available to patients in the United States (U.S.).

https://money.tmx.com/en/quote/AUP/news/4841076584524394/FDA_Approves_Aurinia_Pharmaceuticals_LUPKYNISTM_voclosporin_for_Adult_Patients_with_Active_Lupus_Nephritis

https://endpts.com/fast-on-glaxosmithklines-heels-aurinia-wins-ok-to-steer-a-second-lupus-nephritis-drug-straight-to-the-market/

Soth Africa as made an objection to WHO, re AZN trebling the cost of the vaccine AZN want to charge, its 3 x higher than the UK/EU/USA Covax agreements ..
Big Pharam will get a bad name again and for a vaccine that efficacy is 62% according to the MHRA data. Seems the Like of Credit Suisse miss key fact,s or have AZN been giving them sweetners again

Pfizer would be hard pushed to find the capital to buy GSK, even with the success of Biontech/Pfizer vaccine, Pfizer share price is 10 % below where it stood a year ago

With GSK owning 68% of GSK Consumer Health care, [fizer could always make a sole bid for that, but admits it needs the capital in it medium term plan going forward..
A Merger would be ahead of a takeover, but i dont personally see that being allowed and it would be strongly obected to in the USA